A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
- Citation:
- Cancer vol 112 (8) 1772-9
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA-15083, CA-25224, CA-35101, CA-35103, CA-35113, CA-35119, CA-35195, CA-35269, CA-35415, CA-35431, CA-35448, CA-37404, CA-52352, CA-52654, CA-60276, CA-63848
- Corr. Author:
- Authors:
- Scott H Okuno Robert Delaune Jeff A Sloan Nathan R Foster Matthew J Maurer Marie-Christine Aubry Kendrith M Rowland Gamini S Soori Daniel A Nikcevich Carl G Kardinal Donald W Northfelt Alex A Adjei
- Networks:
- Study
- NCCTG-N0021
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Aged, Aged, 80 and over, Antibiotics, Antineoplastic, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Disease Progression, Epirubicin, Female, Follow-Up Studies, Humans, Injections, Intravenous, Leukopenia, Male, Mesothelioma, Middle Aged, Neutropenia, Pleural Neoplasms, Quality of Life, Remission Induction, Ribonucleotide Reductases, Survival Rate, Thrombocytopenia, Treatment Outcome